The purpose of the study is to test whether the addition of an immunotherapy drug, called tislelizumab, to the standard of care treatment of high-risk endometrial cancer reduces the risk of the disease coming back, and to determine if the new course of therapy is well-tolerated by participants.

Trial Status
Trial Phase
Phase 2 Drug Trial
Registry Listing
ERM Project ID
Trial contact details
Contact Person
Donna Harvey
What you need to know

Who can take part?

Any patients who have been diagnosed with high-risk endometrial cancer who have received surgery for the condition, and also require radiation and then chemotherapy. This trial can only enrol patients who have surgery in the previous 8 weeks.

What is involved for you?

Patients have standard  treatment for their disease, and 2/3 of patients in the trial also receive an additional immunotherapy medication (tislelizumab). Standard of care chemotherapy involves attending the clinic every 3 weeks for chemotherapy for 4 cycles. For patients who are receiving the  additional immunotherapy medication (tislelizumab), you will need to continue to attend the clinic for an additional 8 cycles. While in the clinic you will have a physical assessment, blood collection and complete a quality of life survey. 

All research clinical trials news

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.



Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.



Mater launches trial of Australian-first flu vaccine

Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...



Stephanie Guilas is improving outcomes for mums and bubs through research

Displaying results 1-3 (of 17)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|